Broadwood Partners, L.P. Acquires 108,720 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 108,720 shares of the firm’s stock in a transaction on Thursday, March 20th. The shares were purchased at an average price of $17.96 per share, for a total transaction of $1,952,611.20. Following the purchase, the insider now owns 12,182,995 shares in the company, valued at $218,806,590.20. This trade represents a 0.90 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The shares were bought at an average cost of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The shares were bought at an average cost of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The shares were bought at an average cost of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The shares were bought at an average cost of $21.50 per share, with a total value of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. bought 21,155 shares of STAAR Surgical stock. The stock was acquired at an average cost of $21.46 per share, with a total value of $453,986.30.

STAAR Surgical Trading Down 1.1 %

NASDAQ:STAA opened at $17.72 on Friday. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68. The company has a market cap of $874.04 million, a price-to-earnings ratio of -43.22 and a beta of 0.66. The stock has a fifty day simple moving average of $19.87 and a 200-day simple moving average of $25.70.

Institutional Trading of STAAR Surgical

Institutional investors and hedge funds have recently made changes to their positions in the business. Quarry LP bought a new stake in shares of STAAR Surgical during the third quarter worth $50,000. Quest Partners LLC bought a new stake in shares of STAAR Surgical during the third quarter worth $128,000. Larson Financial Group LLC lifted its position in shares of STAAR Surgical by 78.3% during the third quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after purchasing an additional 2,135 shares during the last quarter. FMR LLC lifted its position in shares of STAAR Surgical by 79.3% during the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock worth $263,000 after purchasing an additional 3,136 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of STAAR Surgical during the fourth quarter worth $180,000. 96.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on STAA shares. StockNews.com lowered shares of STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. BTIG Research lowered shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Mizuho lowered shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $45.00 to $17.00 in a research note on Wednesday, February 12th. Piper Sandler dropped their price objective on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, STAAR Surgical presently has a consensus rating of “Hold” and an average price target of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.